AbbVie shreds alpha-synuclein Parkinson's pact on cusp of phase 2, thinning field led by Roche

AbbVie is bowing out of the alpha-synuclein race. Having taken a drug candidate to the cusp of phase 2, AbbVie has terminated its collaboration with BioArctic, leaving a clutch of rivals such as Novartis and Roche to compete over the Parkinson’s disease opportunity.